Comparative Pharmacology
Head-to-head clinical analysis: IMURAN versus NEORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMURAN versus NEORAL.
IMURAN vs NEORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imuran (azathioprine) is a purine antimetabolite that inhibits DNA synthesis by interfering with purine metabolism. It is converted in vivo to 6-mercaptopurine (6-MP), which is further metabolized to thioinosinic acid and thioguanine nucleotides. These metabolites inhibit de novo purine synthesis and incorporation of purines into nucleic acids, thereby suppressing T-cell proliferation and antibody production.
Cyclosporine, the active ingredient in Neoral, is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NF-AT (nuclear factor of activated T-cells). This inhibits transcription of interleukin-2 and other cytokines, reducing T-cell activation and proliferation.
Initially 3-5 mg/kg/day orally once daily; maintenance dose 1-3 mg/kg/day orally once daily. IV dose equivalent to oral.
Initial dose 10-15 mg/kg/day orally divided q12h, then taper by 5% weekly to maintenance of 3-5 mg/kg/day divided q12h. For psoriasis: 2.5 mg/kg/day orally divided q12h. For rheumatoid arthritis: 2.5-5 mg/kg/day orally divided q12h. Administer consistently with or without food.
None Documented
None Documented
Azathioprine: 0.16–0.75 h; 6-mercaptopurine: 1.5–4.7 h (terminal). Extended up to 5 h in renal impairment. Context: short half-life allows daily dosing; clinical effect persists due to active metabolites.
Terminal elimination half-life: 8.4 hours (range 6–24 hours) in healthy volunteers; prolonged in hepatic impairment (up to 20 hours).
Primarily renal excretion of inactive metabolites; 50% as 6-thiouric acid and other metabolites; <2% unchanged. Minor biliary/fecal elimination (<10% total).
Primarily biliary/fecal (94%): 94% of dose eliminated in feces via bile, 6% in urine (0.1% unchanged). Minimal renal elimination of parent drug.
Category C
Category C
Immunosuppressant
Immunosuppressant